GET DAILY SIGNALSRelay Therapeutics (RLAY): Analyst Consensus Suggests +55% Upside to $28 Target
Key Takeaways
- The central target of $28 is the arithmetic mean of ten verified analyst price targets reviewed, which averaged roughly $28.40 before rounding.
- The latest verified price is about $18.09, meaning the target requires an upside of approximately 55% — a very large move.
- Recent individual analyst targets range from about $25 to $31, reflecting a wide but entirely bullish-to-cautious spread.
- The strongest supporting factor is the multi-indication clinical opportunity for zovegalisib, the company's lead precision-oncology candidate.
- The biggest risks are binary clinical-trial outcomes, persistent operating losses, and a valuation that has already re-rated sharply over the past year.
- You can read more about the company's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages.
- Explore Trending AI Robots to see how automated trading systems are applying AI to changing market conditions.
Analyst Price Targets and Consensus View
Relay Therapeutics, Inc. (RLAY) is a clinical-stage precision-medicines company rather than an exchange-traded fund, so this analysis is built on individual sell-side price targets. Across ten recent, identifiable targets, the figures range from $25 to $31. The specific targets reviewed include $25 (BofA), $26 (Citizens JMP, Guggenheim, and Raymond James), $29 (H.C. Wainwright and Canaccord Genuity), $30 (Barclays), and $31 (J.P. Morgan, Goldman Sachs, and JonesTrading). The arithmetic mean is approximately $28.40, which rounds to a central target of $28.
The RLAY average analyst price target is broadly consistent with independent aggregators, which report consensus figures in the high-$26 to low-$28 range. Sentiment is overwhelmingly positive, with a "Strong Buy" consensus and no sell ratings among active coverage. Even so, the dispersion is meaningful: the highest targets reflect confidence that zovegalisib can become a multi-indication growth franchise, while the lower targets discount execution and clinical risk. Several firms — including J.P. Morgan, Goldman Sachs, and Barclays — raised their targets during 2026 following positive clinical updates, while JonesTrading lifted its target from $20 to $31 in November 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With the stock near $18.09, reaching $28 would require a gain of roughly 55%, a very large move for a single name over a typical research horizon. The shares have already experienced a dramatic re-rating: from a 52-week low near $6.17 to a high around $21.27, the stock has more than tripled off its trough. The path toward the target is unlikely to be linear. It will depend heavily on data readouts for zovegalisib, a pan-mutant PI3Kα inhibitor in development for breast cancer, solid tumors, and vascular malformations, as well as on continued progress across the broader pipeline.
What Could Support a Move Toward the Target
Analysts point to zovegalisib as a potential multi-indication growth driver, with ongoing and planned Phase 3 trials and a possible accelerated pathway in vascular malformations. The company also runs earlier programs, including an FGFR2 inhibitor (lirafugratinib) and candidates targeting NRAS and Fabry disease. A $275 million equity raise in 2026 strengthened the balance sheet, reducing near-term financing overhang and supporting pipeline execution. A steady sequence of analyst target increases through the second half of 2026 signals improving conviction as catalysts approach.
What Could Prevent the Target From Being Reached
The principal obstacle is clinical risk: if key Phase 3 breast cancer data underwhelm, or if regulators push back on the proposed vascular-malformations path, the bull case weakens materially. The company remains deeply unprofitable, reporting a quarterly net loss of about $0.37 per share in late 2026 against a full-year consensus EPS loss near $1.60, and it generates minimal revenue. Valuation has also re-rated quickly, so any disappointment could trigger a sharp de-rating. Finally, the wide $25-to-$31 target dispersion shows analysts disagree on how much of the opportunity is already priced in.
Technical Levels and Market Structure
The shares sit below their 52-week high near $21.27, which now acts as an overhead resistance zone along with the round-number $20 level. A sustained move through that band would be an important structural step toward the target. On the downside, the prior consolidation area in the mid-teens represents a more durable support zone. The stock carries a beta of roughly 1.7, meaning it tends to move with amplified volatility relative to the broader market, which is typical for clinical-stage biotech.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms apply different assumptions. Investors should watch quarterly results and guidance, further analyst revisions, and — most importantly — clinical data readouts for zovegalisib across breast cancer and vascular indications. Regulatory feedback on the accelerated-approval pathway and any additional financing activity are also material. Because outcomes are event-driven rather than earnings-driven, timing is inherently uncertain. From what I see, using Tickeron’s AI Trend Prediction Engine helps flag potential momentum shifts ahead of these events.
AI Daily Buy/Sell Signals
AI Daily Buy/Sell Signals have become a regular part of my workflow for names like this. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, catalyst-driven name like RLAY, it helps me spot shifting trends and momentum more efficiently than manual screening alone. Traders can use these signals to discover opportunities, monitor existing positions, and react to changing market structure without getting overwhelmed by the noise.
Final Assessment
The question of whether Relay Therapeutics can reach $28 is fundamentally a question about whether zovegalisib can validate a multi-indication franchise. The central target, derived from ten analyst targets averaging about $28.40, implies a roughly 55% move from the current price near $18 — a very large, catalyst-dependent advance. The strongest supports are the lead asset's breadth, a strengthened balance sheet, and an overwhelmingly bullish analyst consensus. The principal obstacles are binary clinical risk, ongoing losses, and an already-strong share-price run. With targets spanning $25 to $31, even bulls disagree on the magnitude. The next data readouts and regulatory updates will be decisive; the outcome is not predetermined.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
RLAY in -9.33% downward trend, declining for three consecutive days on November 12, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where RLAY declined for three days, in 281 of 322 cases, the price declined further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 42 of 53 cases where RLAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RLAY as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
RLAY moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
RLAY broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for RLAY just turned positive on November 09, 2026. Looking at past instances where RLAY's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.
The 10-day moving average for RLAY crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +19.94% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLAY advanced for three days, in 237 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 181 of 228 cases where RLAY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.580) is normal, around the industry mean (3.498). P/E Ratio (-11.923) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (333.333) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RLAY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage precision medicines company, which focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets
Industry Biotechnology
Advertisement